SCHEMBL4849523

SCHEMBL4849523

O=C1Nc2cc(N3CCCC3=O)ccc2Nc2cc(Cl)ccc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 4/20 0.62
CES1 P23141 2/20 0.43
PDK2 Q15119 1/20 0.41
LRRK2 Q5S007 1/20 0.40
LMNA P02545 3/20 0.39
ALDH1A1 P00352 3/20 0.39
HTT P42858 1/20 0.39
HPGD P15428 2/20 0.39
TSHR P16473 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
PRKAB2 O43741 1/20 0.39
PRKAG1 P54619 1/20 0.39
PRKAA2 P54646 1/20 0.39
PRKAA1 Q13131 1/20 0.39
PRKAG3 Q9UGI9 1/20 0.39
PRKAG2 Q9UGJ0 1/20 0.39
PRKAB1 Q9Y478 1/20 0.39
MAPT P10636 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4857284 0.96 CHEK1 (0.58) CHEK1CES1PDK2LRRK2LMNA
SCHEMBL4851463 0.83 CHEK1 (0.56) CHEK1CES1LRRK2ALDH1A1MAPT
SCHEMBL4857489 0.81 CHEK1 (0.81) CHEK1PRKAA1
SCHEMBL4848926 0.80 CHEK1 (0.55) CHEK1PDK2
SCHEMBL4857624 0.77 CHEK1 (0.60) CHEK1CES1LRRK2TSHR
SCHEMBL4855834 0.75 CHEK1 (0.50) CHEK1CES1LRRK2TGM2
SCHEMBL4857611 0.74 CHEK1 (0.65) CHEK1CES1LRRK2TGM2
SCHEMBL4851954 0.74 CHEK1 (0.65) CHEK1CES1LRRK2TGM2
SCHEMBL4857109 0.74 CHEK1 (0.76) CHEK1
SCHEMBL4847603 0.73 CHEK1 (0.45) CHEK1CES1LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed
US-20040254159-A1 Heterocyclic kinase inhibitors ABBOTT LABORATORIES 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254159-A1 Heterocyclic kinase inhibitors MAP3K20, MAP3K19, MAP3K1 CHEK1 46/4885CES1 1804/4885PDK2 269/4885
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 CHEK1 38/4885CES1 2761/4885PDK2 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.